David A. Siegel Kymera Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 224,300 shares of KYMR stock, worth $13.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
224,300
Previous 183,300
22.37%
Holding current value
$13.6 Million
Previous $5.02 Million
95.14%
% of portfolio
0.02%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding KYMR
# of Institutions
218Shares Held
72.2MCall Options Held
178KPut Options Held
64.6K-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$415 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$402 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$397 Million5.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$340 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$333 Million9.44% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $3.31B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...